Cargando…

Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation

Racemic (K)‐opioid receptor (KOR) agonist 2‐(3,4‐dichlorophenyl)‐1‐[(4aRS,8SR,8aSR)‐8‐(pyrrolidin‐1‐yl)‐3,4,4a,5,6,7,8,8a‐octahydroquinolin‐1(2H)‐yl]ethan‐1‐one ((±)‐4) was prepared in a diastereoselective synthesis. The first key step of the synthesis was the diastereoselective hydrogenation of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Benedikt, Schepmann, Dirk, Bernal, Freddy A., Schmidt, Thomas J., Che, Tao, Loser, Karin, Wünsch, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496650/
https://www.ncbi.nlm.nih.gov/pubmed/32492288
http://dx.doi.org/10.1002/cmdc.202000300
_version_ 1783583144846295040
author Martin, Benedikt
Schepmann, Dirk
Bernal, Freddy A.
Schmidt, Thomas J.
Che, Tao
Loser, Karin
Wünsch, Bernhard
author_facet Martin, Benedikt
Schepmann, Dirk
Bernal, Freddy A.
Schmidt, Thomas J.
Che, Tao
Loser, Karin
Wünsch, Bernhard
author_sort Martin, Benedikt
collection PubMed
description Racemic (K)‐opioid receptor (KOR) agonist 2‐(3,4‐dichlorophenyl)‐1‐[(4aRS,8SR,8aSR)‐8‐(pyrrolidin‐1‐yl)‐3,4,4a,5,6,7,8,8a‐octahydroquinolin‐1(2H)‐yl]ethan‐1‐one ((±)‐4) was prepared in a diastereoselective synthesis. The first key step of the synthesis was the diastereoselective hydrogenation of the silyl ether of 1,2,3,4‐tetrahydroquinoin‐8‐ol ((±)‐9) to afford cis,cis‐configured perhydroquinoline derivative (±)‐10. Removal of the TBDMS protecting group led to a β‐aminoalcohol that reacted with SO(2)Cl(2) to form an oxathiazolidine. Nucleophilic substitution with pyrrolidine resulted in the desired cis,trans‐configured perhydroquinoline upon inversion of the configuration. In order to obtain enantiomerically pure KOR agonists 4 (99.8 % ee) and ent‐4 (99.0 % ee), 1,2,3,4‐tetrahydroquinolin‐8‐ols (R)‐8 (99.1 % ee) and (S)‐8 (98.4 % ee) were resolved by an enantioselective acetylation catalyzed by Amano lipase PS‐IM. The absolute configuration was determined by CD spectroscopy. The 4aR,8S,8aS‐configured enantiomer 4 showed sub‐nanomolar KOR affinity (K (i)=0.81 nM), which is more than 200 times higher than the KOR affinity of its enantiomer ent‐4. In the cAMP assay and the Tango β‐arrestin‐2 recruitment assay, 4 behaved as a KOR agonist. Upon incubation of human macrophages, human dendritic cells, and mouse myeloid immune cells with 4, the number of cells expressing co‐stimulatory receptor CD86 and proinflammatory cytokines interleukin 6 and tumor necrosis factor α was significantly reduced; this indicates the strong anti‐inflammatory activity of 4. The anti‐inflammatory effects correlated well with the KOR affinity: (4aR,8S,8aS)‐4 was slightly more potent than the racemic mixture (±)‐4, and the distomer ent‐4 was almost inactive.
format Online
Article
Text
id pubmed-7496650
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74966502020-09-25 Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation Martin, Benedikt Schepmann, Dirk Bernal, Freddy A. Schmidt, Thomas J. Che, Tao Loser, Karin Wünsch, Bernhard ChemMedChem Full Papers Racemic (K)‐opioid receptor (KOR) agonist 2‐(3,4‐dichlorophenyl)‐1‐[(4aRS,8SR,8aSR)‐8‐(pyrrolidin‐1‐yl)‐3,4,4a,5,6,7,8,8a‐octahydroquinolin‐1(2H)‐yl]ethan‐1‐one ((±)‐4) was prepared in a diastereoselective synthesis. The first key step of the synthesis was the diastereoselective hydrogenation of the silyl ether of 1,2,3,4‐tetrahydroquinoin‐8‐ol ((±)‐9) to afford cis,cis‐configured perhydroquinoline derivative (±)‐10. Removal of the TBDMS protecting group led to a β‐aminoalcohol that reacted with SO(2)Cl(2) to form an oxathiazolidine. Nucleophilic substitution with pyrrolidine resulted in the desired cis,trans‐configured perhydroquinoline upon inversion of the configuration. In order to obtain enantiomerically pure KOR agonists 4 (99.8 % ee) and ent‐4 (99.0 % ee), 1,2,3,4‐tetrahydroquinolin‐8‐ols (R)‐8 (99.1 % ee) and (S)‐8 (98.4 % ee) were resolved by an enantioselective acetylation catalyzed by Amano lipase PS‐IM. The absolute configuration was determined by CD spectroscopy. The 4aR,8S,8aS‐configured enantiomer 4 showed sub‐nanomolar KOR affinity (K (i)=0.81 nM), which is more than 200 times higher than the KOR affinity of its enantiomer ent‐4. In the cAMP assay and the Tango β‐arrestin‐2 recruitment assay, 4 behaved as a KOR agonist. Upon incubation of human macrophages, human dendritic cells, and mouse myeloid immune cells with 4, the number of cells expressing co‐stimulatory receptor CD86 and proinflammatory cytokines interleukin 6 and tumor necrosis factor α was significantly reduced; this indicates the strong anti‐inflammatory activity of 4. The anti‐inflammatory effects correlated well with the KOR affinity: (4aR,8S,8aS)‐4 was slightly more potent than the racemic mixture (±)‐4, and the distomer ent‐4 was almost inactive. John Wiley and Sons Inc. 2020-07-02 2020-08-05 /pmc/articles/PMC7496650/ /pubmed/32492288 http://dx.doi.org/10.1002/cmdc.202000300 Text en © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Martin, Benedikt
Schepmann, Dirk
Bernal, Freddy A.
Schmidt, Thomas J.
Che, Tao
Loser, Karin
Wünsch, Bernhard
Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
title Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
title_full Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
title_fullStr Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
title_full_unstemmed Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
title_short Enantiomerically Pure Quinoline‐Based κ‐Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
title_sort enantiomerically pure quinoline‐based κ‐opioid receptor agonists: chemoenzymatic synthesis and pharmacological evaluation
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496650/
https://www.ncbi.nlm.nih.gov/pubmed/32492288
http://dx.doi.org/10.1002/cmdc.202000300
work_keys_str_mv AT martinbenedikt enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation
AT schepmanndirk enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation
AT bernalfreddya enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation
AT schmidtthomasj enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation
AT chetao enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation
AT loserkarin enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation
AT wunschbernhard enantiomericallypurequinolinebasedkopioidreceptoragonistschemoenzymaticsynthesisandpharmacologicalevaluation